What question did this study set out to answer?

Evaluate the therapeutic efficacy, clinical applications, and biological limitations of interleukin-6 inhibitors across inflammatory diseases and malignancies.

January 15, 2015Clinical Cancer Research

Interleukin-6 as a Therapeutic Target

View Full Paper

Ask AI

Bookmark

Evaluate the therapeutic efficacy, clinical applications, and biological limitations of interleukin-6 inhibitors across inflammatory diseases and malignancies.
Synthesized clinical evidence on registered IL-6 and IL-6 receptor antagonists, including siltuximab and tocilizumab.
Evaluated biomarker dynamics—specifically C-reactive protein (CRP) suppression—and clinical outcomes across Castleman disease, rheumatoid arthritis, and plasma cell cancers.
IL-6 inhibition reliably suppresses systemic inflammation, acute phase proteins, and anemia, demonstrating robust efficacy and safety in rheumatoid arthritis and Castleman disease.
Large randomized trials in plasma cell cancers showed no therapeutic efficacy despite complete in vivo CRP suppression and initial anti-proliferative responses.
Tumor cell plasticity and the selection of cancer subclones driven by alternative growth factors account for the lack of clinical benefit in oncology.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review highlights the clinical efficacy of interleukin-6 inhibitors in inflammatory disorders versus their limited success in plasma cell cancers, indicating tumor plasticity drives resistance.

Cite This Study

Rossi et al. (2015) studied this question.

synapsesocial.com/papers/69d6eb198dca315383ed950e https://doi.org/10.1158/1078-0432.ccr-14-2291

View Full Paper

Ask AI

Bookmark

Implication

Review highlights the clinical efficacy of interleukin-6 inhibitors in inflammatory disorders versus their limited success in plasma cell cancers, indicating tumor plasticity drives resistance.

Interleukin-6 as a Therapeutic Target

Key Points

Discussion

Implication

Cite This Study

Interleukin-6 as a Therapeutic Target

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider